SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): June 6, 2016
ARCH THERAPEUTICS, INC.
(Exact name of registrant as specified in
|(State or other jurisdiction
|235 Walnut Street, Suite 6
|(Address of principal executive offices)
Registrant’s telephone number, including
area code: (617) 431-2313
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
On June 6, 2016, Arch Therapeutics, Inc. (the “Company”)
issued a press release announcing that the Company has completed patient enrollment in its clinical trial in Ireland using AC5™. The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
||Financial Statements and Exhibit|
||Press Release issued by Arch Therapeutics, Inc. on June 6, 2016|
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
||ARCH THERAPEUTICS, INC.
|Dated: June 6, 2016
||/s/ Terrence W. Norchi, M.D.
||Name: Terrence W. Norchi, M.D.
||Title: President, Chief Executive Officer
||Press Release issued by Arch Therapeutics, Inc. on June 6,